1 min read
Add as a preferred source on GoogleAcumen Posts Q3 GAAP Loss Per Share 2 Cents Below Estimate
Cash, cash equivalents and marketable securities totaled $78.6 million on Sept. 30, 2026.
Acumen Pharmaceuticals expects its $78.6 million balance to support clinical and operating activities into early 2027 after posting a third-quarter GAAP loss of 35 cents per share, 2 cents narrower than estimated.
The balance included cash, cash equivalents and marketable securities as of Sept. 30, 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.